Antares - strong buy Febr. 2015 - 500 Beiträge pro Seite
eröffnet am 20.02.15 17:31:27 von
neuester Beitrag 29.09.15 09:01:34 von
neuester Beitrag 29.09.15 09:01:34 von
Beiträge: 6
ID: 1.208.018
ID: 1.208.018
Aufrufe heute: 0
Gesamt: 1.427
Gesamt: 1.427
Aktive User: 0
ISIN: US0366421065 · WKN: 903128
5,2500
EUR
-0,94 %
-0,0500 EUR
Letzter Kurs 24.05.22 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7500 | +36,36 | |
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 0,7199 | +23,38 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8410 | -17,06 | |
| 9,7200 | -19,60 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Feedback
Strong buy
Antares Pharma Inc Receives Average Target Price of $5.5
February 4, 2015 by Joe Willams
Antares Pharma Inc (NASDAQ:ATRS) should head towards $5.5 per share according to 3 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $4 per share. The higher price estimate target is at $7 according to the Analysts.The information is based on average recommendation on company rating and price target for short term (6 to 12 months) .
Shares of Antares Pharma Inc (NASDAQ:ATRS) have spiked on strong buying. The shares maintained upward bias since opening the day higher at $2.33 and closed with hefty gains of 0.01 points or 0.43%, at $2.34. The positive momentum was complimented by a strong volume of 650,689 shares. The previous day close of the price was $2.33. Market participants should note that the 52-week high of the shares is at $4.96. Antares Pharma Inc (NASDAQ:ATRS) has a market cap of $308 million and the total number of outstanding shares is 131,684,000. The 52-week low of the share price has been registered at $1.82.
Antares Pharma Inc (NASDAQ:ATRS), A sharp reduction of 375,026 shares or 3.9% was observed in the short interest of Antares Pharma, Inc. The interest on January 15,2015 came in at 9,192,138 shares and as per the average daily trading of 1,088,104 shares, the days to cover are 8. The reduced interest is 7.8% of the floated shares. The data of December 31,2014 put the interest at 9,567,164 shares.
Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Companys subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol.
Antares Pharma Inc Receives Average Target Price of $5.5
February 4, 2015 by Joe Willams
Antares Pharma Inc (NASDAQ:ATRS) should head towards $5.5 per share according to 3 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $4 per share. The higher price estimate target is at $7 according to the Analysts.The information is based on average recommendation on company rating and price target for short term (6 to 12 months) .
Shares of Antares Pharma Inc (NASDAQ:ATRS) have spiked on strong buying. The shares maintained upward bias since opening the day higher at $2.33 and closed with hefty gains of 0.01 points or 0.43%, at $2.34. The positive momentum was complimented by a strong volume of 650,689 shares. The previous day close of the price was $2.33. Market participants should note that the 52-week high of the shares is at $4.96. Antares Pharma Inc (NASDAQ:ATRS) has a market cap of $308 million and the total number of outstanding shares is 131,684,000. The 52-week low of the share price has been registered at $1.82.
Antares Pharma Inc (NASDAQ:ATRS), A sharp reduction of 375,026 shares or 3.9% was observed in the short interest of Antares Pharma, Inc. The interest on January 15,2015 came in at 9,192,138 shares and as per the average daily trading of 1,088,104 shares, the days to cover are 8. The reduced interest is 7.8% of the floated shares. The data of December 31,2014 put the interest at 9,567,164 shares.
Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Companys subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol.
Quelle vergessen und in Deutsch wäre toll 
aber danke schon mal für die Info!
Gruß Bernecker1977
aber danke schon mal für die Info!Gruß Bernecker1977
Antwort auf Beitrag Nr.: 49.131.452 von Geheimnisvoller am 20.02.15 17:31:27
Positiv:
-Chart mit möglicher Cup Handle
-MK ca 290 mio €
-die machen schon Umsatz, aber noch keine Gewinn, wenn ich das richtig sehe auf
die Schnelle
-Top Institutional Holders
Negativ:
-könnte so ne Company sein, die wie Biofrontera marktreife Produkte hat,
aber dennoch nicht auf die Beine kommt
Hier mal die Präse aus der HP
http://www.antarespharma.com/files/6414/0673/6552/Antares_Co…
hier mal ein SA Artikel dazu:
Antares Pharma: Preparing For An Inflection Point
http://seekingalpha.com/article/2893056-antares-pharma-prepa…
und die 2 . Seite, die ja oft gesperrt ist:
When considering that Antares and Medac are spending a combined $50 million yearly run-rate to promote and sell their methotrexate (NYSE:MTX) auto-injectors, it's pretty clear that there is an issue somewhere. Given that the benefits to injectable mtx are well known to rheumatologists, I suspect that the issue lies on the payor side. Antares acknowledged this when the company presented at the JP Morgan healthcare conference on January 15, and outlined steps it will take to improve Otrexup going forward:
Bring the sales team in-house as the underperforming sales reps from the contracted Quintiles team are let go, while the rest are retained.
Increase the number of sales territories.
Improve hub services to assist physicians with reimbursement process.
Contract with Managed Care Organizations to reduce prior authorization hurdles.
While these changes will certainly take some time to implement and bear fruit, I believe they should eventually get Otrexup back on track and allow it to become a profitable product. As for the on-going impact that Rasuvo will have, I think both products will slowly start to gain traction and rise in tandem, unless Medac suddenly decides to offer steep discounts in order to take market share. For now, it appears that Medac will try the legal approach after it announced the filing of a preliminary injunction (PI) against Antares. Court dockets indicate that the Markman hearing will be on March 6, which I expect will cause volatility in Antares stock price as that date approaches. While it is certainly possible that Medac may be successful in getting the PI granted, my opinion remains that it is a low probability. Additionally, Antares was successful in getting an Inter Partes Review of Medac's patent, and as quoted from the decision on January 6, 2015:
page 2 / 11
| Next »
LG S.
Hallo Geheimnissvoller!
Sieht auf den ersten Blick interessant ausPositiv:
-Chart mit möglicher Cup Handle
-MK ca 290 mio €
-die machen schon Umsatz, aber noch keine Gewinn, wenn ich das richtig sehe auf
die Schnelle
-Top Institutional Holders
Holder Shares % Out Value* Reported
Deerfield Management 8,104,318 6.15 20,828,097 Dec 31, 2014
Broadfin Capital, LLC 4,700,000 3.57 12,079,000 Dec 31, 2014
BlackRock Institutional Trust Company, N.A. 3,974,609 3.02 10,214,745 Dec 31, 2014
Vanguard Group, Inc. (The) 3,959,762 3.01 10,176,588 Dec 31, 2014
BlackRock Fund Advisors 3,243,777 2.46 8,336,506 Dec 31, 2014
Armistice Capital, LLC 2,600,000 1.97 6,682,000 Dec 31, 2014
Harris (William) Investors, Inc. 2,085,886 1.58 5,360,727 Dec 31, 2014
State Street Corporation 1,908,147 1.45 4,903,937 Dec 31, 2014
Northern Trust Corporation 1,268,650 0.96 3,260,430 Dec 31, 2014
Kingdon Capital Management LLC 1,165,738 0.89 2,995,946 Dec 31, 2014
Negativ:
-könnte so ne Company sein, die wie Biofrontera marktreife Produkte hat,
aber dennoch nicht auf die Beine kommt
Hier mal die Präse aus der HP
http://www.antarespharma.com/files/6414/0673/6552/Antares_Co…
hier mal ein SA Artikel dazu:
Antares Pharma: Preparing For An Inflection Point
http://seekingalpha.com/article/2893056-antares-pharma-prepa…
und die 2 . Seite, die ja oft gesperrt ist:
When considering that Antares and Medac are spending a combined $50 million yearly run-rate to promote and sell their methotrexate (NYSE:MTX) auto-injectors, it's pretty clear that there is an issue somewhere. Given that the benefits to injectable mtx are well known to rheumatologists, I suspect that the issue lies on the payor side. Antares acknowledged this when the company presented at the JP Morgan healthcare conference on January 15, and outlined steps it will take to improve Otrexup going forward:
Bring the sales team in-house as the underperforming sales reps from the contracted Quintiles team are let go, while the rest are retained.
Increase the number of sales territories.
Improve hub services to assist physicians with reimbursement process.
Contract with Managed Care Organizations to reduce prior authorization hurdles.
While these changes will certainly take some time to implement and bear fruit, I believe they should eventually get Otrexup back on track and allow it to become a profitable product. As for the on-going impact that Rasuvo will have, I think both products will slowly start to gain traction and rise in tandem, unless Medac suddenly decides to offer steep discounts in order to take market share. For now, it appears that Medac will try the legal approach after it announced the filing of a preliminary injunction (PI) against Antares. Court dockets indicate that the Markman hearing will be on March 6, which I expect will cause volatility in Antares stock price as that date approaches. While it is certainly possible that Medac may be successful in getting the PI granted, my opinion remains that it is a low probability. Additionally, Antares was successful in getting an Inter Partes Review of Medac's patent, and as quoted from the decision on January 6, 2015:
page 2 / 11
| Next »
LG S.
http://www.antarespharma.com/files/6414/0673/6552/Antares_Co…
und
https://de.finance.yahoo.com/q/ao?s=ATRS%2C+&ql=1
ohne Worte
und allen viel Glück
und
https://de.finance.yahoo.com/q/ao?s=ATRS%2C+&ql=1
ohne Worte
und allen viel Glück
Antwort auf Beitrag Nr.: 49.270.160 von Geheimnisvoller am 07.03.15 21:16:14Ausbruch mit etwas Vol. aus Cup Handle
bin am Überlegen nen Trade zu riskieren
Ziel um die 3USD die nächsten Tage, dann mal sehen.
Gruss S.
bin am Überlegen nen Trade zu riskieren
Ziel um die 3USD die nächsten Tage, dann mal sehen.
Gruss S.
Trading Spotlight
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,24 | |
| +4,67 | |
| -100,00 | |
| -0,27 | |
| 0,00 | |
| +0,54 | |
| +0,96 | |
| -1,08 | |
| -0,23 | |
| +1,58 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 239 | ||
| 102 | ||
| 81 | ||
| 78 | ||
| 77 | ||
| 53 | ||
| 40 | ||
| 38 | ||
| 36 | ||
| 34 |
